Voquezna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(6 years from now)

Voquezna is owned by Phathom.

Voquezna contains Vonoprazan Fumarate.

Voquezna has a total of 2 drug patents out of which 0 drug patents have expired.

Voquezna was authorised for market use on 01 November, 2023.

Voquezna is available in tablet;oral dosage forms.

Drug patent challenges can be filed against Voquezna from 03 May, 2026.

The generics of Voquezna are possible to be released after 11 August, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 01, 2026
New Chemical Entity Exclusivity(NCE) May 03, 2027

Drugs and Companies using VONOPRAZAN FUMARATE ingredient

NCE-1 date: 03 May, 2026

Market Authorisation Date: 01 November, 2023

Treatment: NA


More Information on Dosage

VOQUEZNA family patents

Family Patents